Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
CytomX Therapeutics Inc
CTMX
Healthcare
Biotechnology
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic...
candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:CTMX)
New Post
View:
Posts & Comments
Threaded Posts
(224)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 09, 2024 5:30pm
Analysts' Varied Perspectives On CytomX's CX-904 Cancer Stud
Just In: $CTMX Analysts' Varied Perspectives On CytomX's CX-904 Cancer Study: Safety Profile But Caution in Pancreatic Cancer | BenzingaWednesday,@CytomX Therapeutics Inc@(NASDAQ:CTMX
...more
(4)
•••
zalmonella
X
View Profile
View Bullboard History
Post by
zalmonella
on May 09, 2024 1:23am
The report
So. Nothing tilt he end of the year, then nothign til t eend of next year. Hmmph.
BioVaxys Partner SpayVac for Wildlife, Inc., Scales-Up Vaccine Production Capacity
posted Nov 20, 2024 9:00am by
BioVaxys Technology Corp.
-
|
Kenneth Kovan, BioVaxys President & Chief Operating Officer, stated, "SpayVac for Wildlife, already a leader in developing breeding control, will leverage its scaled-up capacity to shorten the product-development cycle allowing them to further expand their pipeline using BioVaxys' technology platforms as engines for ...read more
(224)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on May 06, 2024 12:30am
CTMX Price Target Alert: $8.00. Issued by Jefferies
Just In: $CTMX CTMX Price Target Alert: $8.00. Issued by Jefferies2024-05-06 00:00:04 ET Roger Song from Jefferies issued a price target of $8.00 for CTMX on 2024-05-05 19:42:00. The adjusted price
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Jan 06, 2023 9:02am
CTMX..... Early a.m runner
On watch Going Skiing...no position Cheers !
(4)
•••
zalmonella
X
View Profile
View Bullboard History
Post by
zalmonella
on Feb 02, 2022 12:47pm
From boom to boot
Nice rise throughoutthe week, adn then last trad of the day on the 1st for 780,00 shars at whatever the market would get for it. Absolutely no news. Was someone trying to cover a short all week,
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Jan 26, 2022 8:10am
EMERGING PARADIGMS IN TREATMENT OF MELANOMA!
$CTMX $NKTR $MGNX $IDYA $ALKS Melanoma, a form of skin cancer, accounts for about 1% of skin cancers but is responsible for over 7,650 deaths every year as per an estimate by the American Cancer
...more
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover Options Trading Strategies to Minimize your Tax Burden